You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Angeliq versus Activelle in normotensive postmenopausal women: a prospective, randomized pilot study

Battaglia, Cesare MD, PhD1; Cianciosi, Arianna MD1; Mancini, Fulvia MD, PhD1; Persico, Nicola MD1; Sisti, Giovanni MD1; Facchinetti, Fabio MD2; Busacchi, Paolo MD1

Menopause:
doi: 10.1097/GME.0b013e3181963ef4
Articles
Abstract

Objective: The aim of this study was to compare, in normotensive postmenopausal women, the effects of drospirenone/estradiol and norethisterone acetate/estradiol on blood pressure and other surrogate markers of cerebrovascular and cardiovascular risk.

Methods: Thirty postmenopausal women were submitted to utero-ovarian ultrasonography and to color Doppler evaluation of ophthalmic arteries. Ultrasonographic and Doppler analysis of brachial artery flow-mediated vasodilatation and 24-hour ambulatory blood pressure monitoring were performed. Plasma concentrations of nitrites/nitrates were assayed. The participants were randomly assigned to drospirenone 2 mg/estradiol 1 mg (group 1; n = 15) or norethisterone acetate 0.5 mg/estradiol 1 mg (group 2; n = 15) treatment. The duration of the study was 6 months.

Results: The basal pulsatility index and the back pressure of the ophthalmic artery were similar in groups 1 and 2. After 6 months, no changes were observed. The nitrites/nitrates values were not different between groups 1 and 2 both in basal conditions and after therapy. The brachial artery flow-mediated vasodilatation and the pulsatility index of the brachial artery did not show any difference in groups 1 and 2 both in basal conditions and after the therapy. The 24-hour blood pressure monitoring showed no significant differences in the 24-hour time, daytime, and nighttime values either in basal conditions or after therapy. All participants were found to be dippers normally (nocturnal reduction ≥10% in comparison with diurnal values). The wake-up blood pressure values were similar in the studied participants.

Conclusions: A 6-month hormone therapy with drospirenone/estradiol or norethisterone acetate/estradiol is equally effective and does not seem to alter the surrogate markers of cardiovascular and cerebrovascular risk.

In Brief

A 6-month hormone therapy with drospirenone/estradiol or norethisterone acetate/estradiol seems to not alter the surrogate markers of cardiovascular and cerebrovascular risk.

Author Information

From the 1Department of Obstetrics and Gynecology, Alma Mater Studiorum, University of Bologna, Bologna, Italy; and 2Department of Obstetrics and Gynecology, University of Modena and Reggio Emilia, Modena, Italy.

Received September 19, 2008; revised and accepted November 19, 2008.

Financial disclosure/conflicts of interest: None reported.

Address correspondence to: Cesare Battaglia, MD, PhD, Department of Obstetrics and Gynecology, Alma Mater Studiorum, University of Bologna, Via Massarenti, 13-40138 Bologna, Italy. E-mail: cesare.battaglia@unibo.it

©2009The North American Menopause Society